YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC)
Status:
Recruiting
Trial end date:
2022-02-28
Target enrollment:
Participant gender:
Summary
The aim of this study is to compare the efficacy and safety of YIV-906 plus standard-of-care
sorafenib versus those of sorafenib alone as a first-line systemic treatment for patients
with Hepatitis B (+) associated advanced hepatocellular carcinoma.
YIV-906 (PHY906, KD018) is an immune system modulator. Clinical and preclinical research
suggests that YIV-906 could act to enhance the body's immune response to fight cancer and
increase the anti-tumor activity of sorafenib and protect and repair the gastrointestinal
tract by reducing inflammation and promoting tissue regeneration.
Inspired by a 1,800-year-old traditional medicine still in use today, YIV-906 is a botanical
drug candidate, composed of an extract of four herbs and administered in oral capsule form.
The CALM (Combination of YIV-906 and Sorafenib to treat Advanced Liver cancer in a
Multi-center study) trial is a multi-regional, randomized, placebo-controlled study.